Literature DB >> 9789879

Cytokines production in chronic schizophrenia patients with or without paranoid behaviour.

C L Cazzullo1, S Scarone, B Grassi, C Vismara, D Trabattoni, M Clerici, M Clerici.   

Abstract

1. Several immunological abnormalities have been found in schizophrenia but their significance still remains largely unknown. In this study the authors analyzed mitogen-stimulated interleukin (IL)-2, Interferon gamma (IFN)-gamma and IL-10 (type 2 cytokine) production in a sample of 37 chronic schizophrenic patients as compared with a sample of 40 age and sex-matched controls with the aim to evaluate whether patients belonging to different diagnostic subtypes (i.e. paranoid patients vs non paranoid patients) could be immunologically different from each other. 2. The findings indicate that paranoid patients produce less IL-10 than the others and thus, from an immunological viewpoint, they are more similar to healthy controls. 3. Furthermore, neuroleptic medications were observed to differently affect IL-2 production; this preliminary finding might stimulate further studies aiming to get a link between different drug profile of action both in terms of clinical and receptorial profile and different immunological effects.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9789879     DOI: 10.1016/s0278-5846(98)00059-1

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  23 in total

Review 1.  [Immunology in schizophrenic disorders].

Authors:  N Müller; M J Schwarz
Journal:  Nervenarzt       Date:  2007-03       Impact factor: 1.214

2.  Immune System and Schizophrenia.

Authors:  Norbert Müller; Markus J Schwarz
Journal:  Curr Immunol Rev       Date:  2010-08

Review 3.  COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date.

Authors:  Michael Riedel; Martin Strassnig; Markus J Schwarz; Norbert Müller
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 4.  Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission.

Authors:  N Muller; M Schwarz
Journal:  Neurotox Res       Date:  2006-10       Impact factor: 3.911

Review 5.  Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view.

Authors:  Jeffrey K Yao; Matcheri S Keshavan
Journal:  Antioxid Redox Signal       Date:  2011-04-21       Impact factor: 8.401

6.  Functional polymorphism in the interleukin-6 and interleukin-10 genes in patients with paranoid schizophrenia--a case-control study.

Authors:  Monika Paul-Samojedny; Malgorzata Kowalczyk; Renata Suchanek; Aleksander Owczarek; Anna Fila-Danilow; Aleksandra Szczygiel; Jan Kowalski
Journal:  J Mol Neurosci       Date:  2010-09       Impact factor: 3.444

Review 7.  Methodological Issues in Cytokine Measurement in Schizophrenia.

Authors:  Maju Mathew Koola
Journal:  Indian J Psychol Med       Date:  2016 Jan-Feb

8.  ATA homozigosity in the IL-10 gene promoter is a risk factor for schizophrenia in Spanish females: a case control study.

Authors:  Berta Almoguera; Rosa Riveiro-Alvarez; Jorge Lopez-Castroman; Pedro Dorado; Rosario Lopez-Rodriguez; Pablo Fernandez-Navarro; Enrique Baca-García; Jose Fernandez-Piqueras; Rafael Dal-Ré; Francisco Abad-Santos; Adrián Llerena; Carmen Ayuso
Journal:  BMC Med Genet       Date:  2011-06-09       Impact factor: 2.103

9.  Association study of interleukin 2 (IL2) and IL4 with schizophrenia in a Japanese population.

Authors:  Yuichiro Watanabe; Ayako Nunokawa; Masako Shibuya; Naoshi Kaneko; Hiroyuki Nawa; Toshiyuki Someya
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-06-20       Impact factor: 5.270

Review 10.  A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders.

Authors:  Norbert Müller; Markus J Schwarz
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-06       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.